Skip to main content
. Author manuscript; available in PMC: 2023 Dec 29.
Published in final edited form as: Br J Haematol. 2023 May 22;202(3):686–689. doi: 10.1111/bjh.18881

Figure 1: Correlation between CD3 immunostaining and survival at 10 years follow-up.

Figure 1:

Ten years follow-up of PFS (months) according to CD3 IHC scores in the R-maintenance arm (A) and in the control (R-chemo without maintenance) arm (B) of the PRIMA trial. High amounts of CD3 (>30%) are significantly associated with PFS in the R-maintenance arm (A), but not in control arm (B). Panel C shows PFS in the subgroup of patients with high CD3 counts (>30%), whereas panel D shows PFS in the subgroup of patients with low counts (≤30%). There is a dramatic benefit of R-maintenance in CD3-high patients (C) when compared to CD3-low pts (D).